Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

(2016) B. Paiva et al.   BLOOD

MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients

(2016) O Landgren et al.   BONE MARROW TRANSPLANTATION

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

(2015) Neha Korde et al.   JAMA Oncology

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases

(2013) Prashant R. Tembhare et al.   LEUKEMIA RESEARCH

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population

(2008) S. Vasu et al.   BLOOD